Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Withdrawn; Phase 1

Conditions: Malignant Pleural Mesothelioma

Treatments: Drug: Pemetrexed/Cisplatin; Radiation: Pleural Intensity Modulated Radiation Therapy; Device: MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT02639767

15-304

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of combining chemotherapy at different doses with a specific type of radiation therapy delivered to the entire lining of the lung to find out what effects, if any, it has on people. This radiation technique is called pleural intensity modulated radiation therapy (IMRT). IMRT specifically targets the lining of the lung (pleura) where the cancer is and reduces the risk of damaging the lung itself. When given after chemotherapy, pleural IMRT has demonstrated promising results with respect to keeping mesothelioma under control longer. However, the investigators want to determine if giving pleural IMRT at the same time as chemotherapy is safe. If safe, further studies will be done to see if chemotherapy and pleural IMRT given at the same time keeps the tumor under control for a longer period of time than chemotherapy followed by pleural IMRT.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed diagnosis of malignant pleural mesothelioma at MSKCC

• No plans for surgical resection

• Stage T1-4, N0-3, M0

• No prior radiation therapy to the chest, breast or supraclavicular fossa that would limit radiation delivery to the full prescription dose

• Prior chemotherapy regimens ≤1

• Age ≥18 years

• Karnofsky performance status ≥ 80%

• Pulmonary function tests as follows: DLCO>50% predicted

• Adequate hematologic, hepatic, and renal function as indicated by the following laboratory values

  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelets ≥ 100,000/mcL
  • Calculated creatinine clearance (CrCl) ≥ 45mL/min (using Cockcroft & Gault method)
  • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless known Gilbert's disease)
  • AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN

Exclusion criteria

• Pregnant or lactating women, or men or women not using effective contraception
• Patients with an active infection that requires systemic antibiotics, antiviral, or antifungal treatments
• Patients with a concurrent active malignancy (with the exception of skin cancer)
• Patients with serious unstable medical illness
• Patients with idiopathic pulmonary fibrosis
• Patients with NYHA heart failure class >2
• Patients with only one kidney that is ipsilateral to the mesothelioma
• Implanted pacemaker and/or defibrillator ipsilateral to the mesothelioma if it cannot be moved
• Patients meeting the following exclusion criteria will be excluded from the MRI portion only:
• Metallic implant, e.g. pacemaker, defibrillator
• Unmanageable claustrophobia
• High risk for nephrogenic systemic fibrosis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

pemetrexed/cisplatin with pleural IMRT

Experimental group

Description:

This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.

Treatment:

Device: MRI

Drug: Pemetrexed/Cisplatin

Radiation: Pleural Intensity Modulated Radiation Therapy